Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909377 | 0.88 | PTPN11 (0.60) | PTPN11EGFRKCNH2 | |
| SCHEMBL20909362 | 0.86 | PTPN11 (0.46) | PTPN11 | |
| SCHEMBL30787770 | 0.84 | PTPN11 (0.72) | PTPN11EGFRKCNH2 | |
| SCHEMBL20899359 | 0.84 | PTPN11 (0.72) | PTPN11EGFRKCNH2 | |
| SCHEMBL20909050 | 0.84 | PTPN11 (0.69) | PTPN11EGFRKCNH2 | |
| SCHEMBL20909042 | 0.81 | PTPN11 (0.71) | PTPN11EGFRKCNH2 | |
| SCHEMBL22594940 | 0.80 | PTPN11 (0.58) | PTPN11EGFRKCNH2 | |
| SCHEMBL20909056 | 0.79 | PTPN11 (0.68) | PTPN11EGFRKCNH2 | |
| SCHEMBL20909325 | 0.78 | PTPN11 (0.53) | PTPN11 | |
| SCHEMBL20909035 | 0.76 | PTPN11 (0.73) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200339552-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-10-29 | — | — | US | disclosed |
| WO-2019075265-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339552-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885EGFR 1072/4885KCNH2 3400/4885 |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885EGFR 1072/4885KCNH2 3400/4885 |
| US-11702411-B2 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 6/4885EGFR 1072/4885KCNH2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.